Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23508720 | 0.85 | KDM1A (0.45) | KDM1ATNKSTNKS2KDM4EGLA | |
| SCHEMBL12791302 | 0.82 | OPRM1 (0.42) | KDM1AOPRM1DRD4TNKSTNKS2 | |
| SCHEMBL3934411 | 0.81 | KDM1A (0.55) | KDM1AOPRM1TNKSTNKS2KIF11 | |
| SCHEMBL397157 | 0.78 | KDM1A (0.51) | KDM1AOPRM1TNKSTNKS2MEN1 | |
| SCHEMBL15523144 | 0.78 | KDM1A (0.51) | KDM1AOPRM1TNKSTNKS2MEN1 | |
| SCHEMBL4270096 | 0.77 | TNKS (0.42) | KDM1AOPRM1DRD4TNKSTNKS2 | |
| SCHEMBL25422577 | 0.77 | KDM1A (0.50) | KDM1ATNKSTNKS2MEN1KMT2A | |
| SCHEMBL29384355 | 0.77 | KDM1A (0.50) | KDM1ATNKSTNKS2MEN1KMT2A | |
| SCHEMBL13209513 | 0.74 | KDM1A (0.47) | KDM1AOPRM1TNKSTNKS2MEN1 | |
| SCHEMBL8842935 | 0.72 | KDM1A (0.46) | KDM1AOPRM1TNKSTNKS2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281476-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-8367691-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| US-8258148-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-04 | — | — | US | disclosed |
| US-7879834-B2 | spiro[indoline-3,4'-piperidine] derivatives, used for the treatment of nervous system disorders, chronic obstructive pulmonary disease, asthma, urinary incontinence, vision defects, Alzheimer's disiease, obesity or as analgesics and antidepressants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-01 | — | — | US | disclosed |
| US-7858635-B2 | Spiro compounds as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100311746-A1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311720-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-7786141-B2 | Dihydrospiroindene modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080015179-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-20070043023-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281476-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | KDM1A 2615/4885OPRM1 66/4885DRD4 1562/4885 |
| US-20100311720-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM4 | KDM1A 2769/4885OPRM1 201/4885DRD4 775/4885 |
| US-20100311746-A1 | MODULATORS OF MUSCARINIC RECEPTORS | CHRM3, CHRM5, CHRM2 | KDM1A 2615/4885OPRM1 66/4885DRD4 1562/4885 |
| US-20080015179-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | KDM1A 2615/4885OPRM1 66/4885DRD4 1562/4885 |
| US-20070043023-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | KDM1A 2615/4885OPRM1 66/4885DRD4 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.